Our drug candidates, NX210 and analogs, meet criteria being highly desirable features for CNS damages treatment



  • Our products are small peptides derived from the most conserved sequence of the thrombospondin repeat (TSRs) of the SCO-spondin, a naturally secreted protein with potent activity during neurogenesis


  • TSRs are active domains involved in various context-dependent pathways and contributing in angiogenesis and axon guidance



  • Our drug candidates have multifunctional activities on neural cells, encompassing:

    • Anti-oxidative properties

    • Anti-apoptotic activities

    • Able to induce cell extension, neurite outgrowth and fasciculation


Our data demonstrates that NX210 is able to promote neurite fasciculation and axonogenesis in a dose-dependent manner [1; 2] as well as to protect neurons against insults [3].


In vivo  in rodents NX210 has been shown to promote nerve fiber regrowth and the recovery of sensorimotor functions and in counteracting behavioral deficits in case of spinal cord injury (SCI) [3].


NX210 is a patented peptide deduced from the thrombospondin repeat domains (TSRs) of the SCO-spondinThis is a first-in class multi-functional agent able to prevents neural cell death and to promote neurite outgrowth. NX210 has been granted Orphan Drug Designation by European Medicine Agency (EMA) for the treatment of spinal cord injury. A Phase I Tolerance clinical trial is planned in patients with Spinal Cord Injury.





In vivo regrowth of nerve fibers through the lesion site



60% of NX210 treated rats recover weight support and fore-hindlimb coordination (BBB >14)

Percentage of rats with a BBB score > 14 along the delay post NX210 treatment

BBB (Basso, Beattie and Bresnahan) Scoring is the reference method used to assess the motor function of rats. BBB over 14 means the return of toe clearance during stepping, predominant paw position, trunk stability, and tail position.